-
Khan et al report a multicenter trial comparing pulmonary vein isolation vs AV junctional ablation with biventricular pacing in patients with atrial fibrillation and heart failure.
-
The Microvolt t-wave Alternans Testing for risk Stratification of Post-Myocardial Infarction Patients (MASTER) trial tested the hypothesis that microvolt T-wave alternans (MTWA) testing could successfully predict arrhythmia occurrence in patients receiving an ICD for primary prevention of sudden cardiac death.
-
-
The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
JUPITER, a trial first presented november 9, 2008, at the american Heart Association meeting in New Orleans, was clearly "the bell of the ball," with multiple television, newspaper, and medical journal reports.
-
Leaders of the American Diabetes Association (ADA) joined with leaders of the European Association for the Study of Diabetes to reconsider the treatment strategy for patients with Type 2 diabetes.
-
The available results from three ezetimibe/simvastatin trials did not provide credible evidence of any adverse effects of ezetimibe on the rate of cancer association with ezetimibe administration at the present time.
-
Colesevelam is a bile-sequestering agent approved in 2000 for the treatment of hypercholesterolemia. It has recently been shown to be effective as add-on therapy for Type 2 diabetics.
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
